386 related articles for article (PubMed ID: 33193296)
1. Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.
Driver JP; de Carvalho Madrid DM; Gu W; Artiaga BL; Richt JA
Front Immunol; 2020; 11():2172. PubMed ID: 33193296
[TBL] [Abstract][Full Text] [Related]
2. Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.
Yang G; Richt JA; Driver JP
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29280974
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs.
Dwivedi V; Manickam C; Dhakal S; Binjawadagi B; Ouyang K; Hiremath J; Khatri M; Hague JG; Lee CW; Renukaradhya GJ
Vet Microbiol; 2016 Apr; 186():157-63. PubMed ID: 27016770
[TBL] [Abstract][Full Text] [Related]
4. Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.
Anderson RJ; Li J; Kedzierski L; Compton BJ; Hayman CM; Osmond TL; Tang CW; Farrand KJ; Koay HF; Almeida CFDSSE; Holz LR; Williams GM; Brimble MA; Wang Z; Koutsakos M; Kedzierska K; Godfrey DI; Hermans IF; Turner SJ; Painter GF
ACS Chem Biol; 2017 Nov; 12(11):2898-2905. PubMed ID: 29043774
[TBL] [Abstract][Full Text] [Related]
5. Unaltered influenza disease outcomes in swine prophylactically treated with α-galactosylceramide.
Gu W; Madrid DMD; Yang G; Artiaga BL; Loeb JC; Castleman WL; Richt JA; Lednicky JA; Driver JP
Dev Comp Immunol; 2021 Jan; 114():103843. PubMed ID: 32871161
[TBL] [Abstract][Full Text] [Related]
6. Profiling of innate and adaptive immune cells during influenza virus infection reveals sex bias in invariant natural killer T (iNKT) cells.
Humeniuk P; Barrett A; Axelsson H; Corciulo C; Drevinge C; Pons ADC; Angeletti D; Scheffler JM; Islander U
Immun Inflamm Dis; 2023 Apr; 11(4):e837. PubMed ID: 37102646
[TBL] [Abstract][Full Text] [Related]
7. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
8. Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.
Calzas C; Chevalier C
Front Immunol; 2019; 10():1605. PubMed ID: 31379823
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
10.
Hughes HR; Brockmeier SL; Loving CL
Front Immunol; 2018; 9():2255. PubMed ID: 30337924
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins.
Nogales A; Martinez-Sobrido L; Topham DJ; DeDiego ML
Viruses; 2018 Dec; 10(12):. PubMed ID: 30545063
[TBL] [Abstract][Full Text] [Related]
12. Invariant NKT cells: regulation and function during viral infection.
Juno JA; Keynan Y; Fowke KR
PLoS Pathog; 2012; 8(8):e1002838. PubMed ID: 22916008
[TBL] [Abstract][Full Text] [Related]
13. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.
Bolton KJ; McCaw JM; Brown L; Jackson D; Kedzierska K; McVernon J
PLoS One; 2015; 10(3):e0120138. PubMed ID: 25811654
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages.
Paget C; Ivanov S; Fontaine J; Renneson J; Blanc F; Pichavant M; Dumoutier L; Ryffel B; Renauld JC; Gosset P; Gosset P; Si-Tahar M; Faveeuw C; Trottein F
J Biol Chem; 2012 Mar; 287(12):8816-29. PubMed ID: 22294696
[TBL] [Abstract][Full Text] [Related]
15. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
16. Influenza Virus: A Master Tactician in Innate Immune Evasion and Novel Therapeutic Interventions.
Hsu AC
Front Immunol; 2018; 9():743. PubMed ID: 29755452
[TBL] [Abstract][Full Text] [Related]
17. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
18. Development of an Alternative Modified Live Influenza B Virus Vaccine.
Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
[TBL] [Abstract][Full Text] [Related]
19. Innate and adaptive T cells in influenza disease.
Nüssing S; Sant S; Koutsakos M; Subbarao K; Nguyen THO; Kedzierska K
Front Med; 2018 Feb; 12(1):34-47. PubMed ID: 29352371
[TBL] [Abstract][Full Text] [Related]
20. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F
Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
